RETRACTED: Transcatheter Decellularized Tissue-Engineered Heart Valve (dTEHV) Grown on Polyglycolic Acid (PGA) Scaffold Coated with P4HB Shows Improved Functionality over 52 Weeks due to Polyether-Ether-Ketone (PEEK) Insert
This record is marked as retracted by the source. Review the publisher’s notice before using its findings.
Source abstract
Abstract
Many congenital heart defects and degenerative valve diseases require replacement of heart valves in children and young adults. Transcatheter xenografts degenerate over time. Tissue engineering might help to overcome this limitation by providing valves with ability for self-repair. A transcatheter decellularized tissue-engineered heart valve (dTEHV) was developed using a polyglycolic acid (PGA) scaffold. A first prototype showed progressive regurgitation after 6 months in-vivo due to a suboptimal design and misguided remodeling process. A new geometry was developed accordingly with computational fluid dynamics (CFD) simulations and implemented by adding a polyether-ether-ketone (PEEK) insert to the bioreactor during cultivation. This lead to more belly-shaped leaflets with higher coaptation areas for this second generation dTEHV. Valve functionality assessed via angiography, intracardiac echocardiography, and MRI proved to be much better when compared the first generation dTEHV, with preserved functionality up to 52 weeks after implantation. Macroscopic findings showed no thrombi or signs of acute inflammation. For the second generation dTEHV, belly-shaped leaflets with soft and agile tissue-formation were seen after explantation. No excessive leaflet shortening occurred in the second generation dTEHV. Histological analysis showed complete engraftment of the dTEHV, with endothelialization of the leaflets and the graft wall. Leaflets consisted of collagenous tissue and some elastic fibers. Adaptive leaflet remodeling was visible in all implanted second generation dTEHV, and most importantly no fusion between leaflet and wall was found. Very few remnants of the PGA scaffold were detected even 52 weeks after implantation, with no influence on functionality. By adding a polyether-ether-ketone (PEEK) insert to the bioreactor construct, a new geometry of PGA-scaffold based dTEHV could be implemented. This resulted in very good valve function of the implanted dTEHV over a period of 52 weeks.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cardiac Valve Diseases and Treatments · Congenital Heart Disease Studies · Tissue Engineering and Regenerative Medicine
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Deutsches Herzzentrum Berlin, Department of Congenital Heart Disease, 13353 Berlin, Germany
Universitätsmedizin Göttingen, Herzzentrum Göttingen, Department of Pediatric Cardiology, 37075 Göttingen, Germany
Funding
Seventh Framework Programme
References (23)
Show source-provided references
1. The incidence of congenital heart disease10.1016/S0735-1097(02)01886-7 ↗
2. Birth prevalence of congenital heart disease worldwide: A systematic review and meta-analysis10.1016/j.jacc.2011.08.025 ↗
3. Implantation of a Tissue-Engineered Tubular Heart Valve in Growing Lambs10.1007/s10439-016-1605-7 ↗
4. Valve replacement in children: A challenge for a whole life10.1016/j.acvd.2012.02.013 ↗
5. Thromboembolic and Bleeding Complications in Patients with Mechanical Heart-Valve Prostheses10.1161/01.CIR.89.2.635 ↗
6. Mechanical versus bioprosthetic aortic valve replacement10.1093/eurheartj/ehx141 ↗
7. Heart valve regeneration
8. Heart valve health, disease, replacement, and repair: A 25-year cardiovascular pathology perspective10.1016/j.carpath.2016.05.002 ↗
9. The future of heart valve replacement: Recent developments and translational challenges for heart valve tissue engineering10.1002/term.2326 ↗
10. PGA (polyglycolic acid)-P4HB (poly-4-hydroxybutyrate)-Based Bioengineered Valves in the Rat Aortic Circulation
11. Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno- and homografts10.1016/j.biomaterials.2012.03.015 ↗
12. Comparative analysis of poly-glycolic acid-based hybrid polymer starter matrices for in vitro tissue engineering10.1016/j.colsurfb.2017.06.046 ↗
13. In situ heart valve tissue engineering using a bioresorbable elastomeric implant—From material design to 12 months follow-up in sheep10.1016/j.biomaterials.2017.02.007 ↗
14. The Effects of Scaffold Remnants in Decellularized Tissue-Engineered Cardiovascular Constructs on the Recruitment of Blood Cells10.1089/ten.tea.2016.0503 ↗
15. First percutaneous implantation of a completely tissue-engineered self-expanding pulmonary heart valve prosthesis using a newly developed delivery system: A feasibility study in sheep10.1007/s12928-016-0396-y ↗
16. Percutaneous pulmonary valve replacement using completely tissue-engineered off-the-shelf heart valves: Six-month in vivo functionality and matrix remodelling in sheep10.4244/EIJV12I1A12 ↗
17. Transcatheter Implantation of Homologous “Off-the-Shelf” Tissue-Engineered Heart Valves With Self-Repair Capacity10.1016/j.jacc.2013.09.082 ↗
18. Improved Geometry of Decellularized Tissue Engineered Heart Valves to Prevent Leaflet Retraction10.1007/s10439-015-1386-4 ↗
19. Recommendations for the echocardiographic assessment of native valvular regurgitation: An executive summary from the European Association of Cardiovascular Imaging10.1093/ehjci/jet105 ↗
20. Emmert, M.Y., Schmitt, B.A., Loerakker, S., Sanders, B., Spriestersbach, H., Fioretta, E.S., Bruder, L., Brakmann, K., Motta, S.E., and Lintas, V. (2018). Computational modeling guides tissue-engineered heart valve design for long-term in vivo performance in a translational sheep model. Sci. Transl. Med., 10.10.1126/scitranslmed.aan4587 ↗
21. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering10.1161/CIRCULATIONAHA.105.591768 ↗
22. Effects of valve geometry and tissue anisotropy on the radial stretch and coaptation area of tissue-engineered heart valves10.1016/j.jbiomech.2013.05.015 ↗
23. A Universal Delivery System for Percutaneous Heart Valve Implantation10.1007/s10439-016-1561-2 ↗